Regencell Bioscience
RGC

$6.33

2.76%

Market Cap: $82.4M

About: Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.

Employees: 12

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 3 [Q1] → 3 (+0) [Q2]

0.01% less ownership

Funds ownership: 0.01% [Q1] → 0% (-0.01%) [Q2]

75% less capital invested

Capital invested by funds: $7.44K [Q1] → $1.89K (-$5.54K) [Q2]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for RGC.

See Analyst Rankings

Financial journalist opinion

Positive

InvestorPlace

1 month ago

What Is Going on With Regencell Bioscience (RGC) Stock Today?

Little-known drug manufacturer Regencell Bioscience (NASDAQ: RGC ) saw its shares skyrocket on Tuesday on no apparent catalyst. However, it's possible that the exceptionally distinct business profile — specializing in traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders — caught the attention of speculators.

See News Rankings

Regencell BioscienceRGC